EyePoint Pharmaceuticals, Inc.
EYPTNASDAQHealthcare● Active
$11.56
$-0.22(-1.88%)
Market Cap$969071259
P/E Ratio—
52W High$19.11
52W Low$7.94
EyePoint Pharmaceuticals, Inc. (EYPT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · EYPT · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $31.37M | $43.27M | $46.02M | $41.40M | $36.94M |
| Cost of Revenue | $2.07M | $3.71M | $4.63M | $8.33M | $8.18M |
| Gross Profit | $29.30M | $39.56M | $41.39M | $33.08M | $28.76M |
| Gross Margin %(computed) | 93.41% | 91.42% | 89.93% | 79.89% | 77.86% |
| Operating Expenses | |||||
| R&D Expenses | $221.04M | $132.93M | $64.66M | $49.64M | $28.50M |
| G&A Expenses | $51.61M | $52.36M | $40.10M | $34.82M | $25.57M |
| Total Operating Expenses | $272.74M | $185.41M | $116.45M | $132.72M | $84.04M |
| Operating Income | ($243.43M) | ($145.85M) | ($75.07M) | ($99.64M) | ($55.28M) |
| Operating Margin %(computed) | -775.98% | -337.06% | -163.13% | -240.65% | -149.64% |
| Interest Income | $11.75M | $15.09M | $6.95M | $2.13M | $0.29M |
| Interest Expense | ($0.03M) | $0.01M | $1.25M | $3.19M | $5.50M |
| Income Before Tax | ($231.68M) | ($130.78M) | ($70.71M) | ($102.25M) | ($58.42M) |
| Income Tax Expense | $0.28M | $0.09M | $0.08M | $0.00M | $0.00M |
| Net Income | ($231.96M) | ($130.87M) | ($70.80M) | ($102.25M) | ($58.42M) |
| Net Margin %(computed) | -739.42% | -302.43% | -153.84% | -246.97% | -158.14% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.17 | $-2.32 | $-1.82 | $-2.74 | $-2.03 |
| Wtd Avg Shares | 73.25M | 56.30M | 38.90M | 37.32M | 28.76M |
| EBITDA | ($243.43M) | ($129.23M) | ($69.00M) | ($96.62M) | ($50.15M) |
| EBITDA Margin %(computed) | -775.98% | -298.63% | -149.94% | -233.36% | -135.76% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more EyePoint Pharmaceuticals, Inc. data
About EyePoint Pharmaceuticals, Inc. (EYPT) Income Statement
EyePoint Pharmaceuticals, Inc. (EYPT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, EYPT reported revenue of $0.03B, gross profit of $0.03B (gross margin 93.41%), and net income of ($0.23B) — a net profit margin of -739.42%.
Frequently asked questions
EYPT · 4 questionsEyePoint Pharmaceuticals, Inc. (EYPT) reported revenue of $0.03B for 2025, down 27.5% year-over-year.
EYPT revenueEYPT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08